We are live on ! Find out more
Jacobs Levy Equity Management

Jacobs Levy Equity Management Portfolio holdings

AUM $23.8B
1-Year Est. Return 25.4%
This Fund
S&P 500
This Quarter Est. Return
+26.16%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$11.4B
AUM Growth
+$1.76B
Cap. Flow
-$330M
Cap. Flow %
-2.89%
Top 10 Hldgs %
18.38%
Holding
1,151
New
138
Increased
341
Reduced
503
Closed
146

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$32.1M
2
INTC icon
Intel
INTC
+$28.7M
3
GILD icon
Gilead Sciences
GILD
+$27.7M
4
APA icon
APA Corp
APA
+$27.5M
5
COST icon
Costco
COST
+$25.1M

Sector Composition

Rank Sector Weight
1 Technology 26.64%
2 Healthcare 14.08%
3 Consumer Discretionary 13.88%
4 Financials 13.05%
5 Industrials 9.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GSIT icon
976
GSI Technology
GSIT
$201M
$144K ﹤0.01%
+19,415
New +$128K
OPBK icon
977
OP Bancorp
OPBK
$235M
$144K ﹤0.01%
18,726
-13,383
-42% -$93.1K
SLNO
978
DELISTED
Soleno Therapeutics
SLNO
$141K ﹤0.01%
+4,873
New +$141K
LYRA
979
DELISTED
LYRA THERAPEUTICS INC
LYRA
$139K ﹤0.01%
+245
New +$138K
SCPH
980
DELISTED
scPharmaceuticals
SCPH
$138K ﹤0.01%
+26,164
New +$205K
FNHC
981
DELISTED
FedNat Holding Company Common Stock
FNHC
$138K ﹤0.01%
23,274
-44,481
-66% -$254K
SNFCA icon
982
Security National Financial
SNFCA
$248M
$135K ﹤0.01%
+21,742
New +$122K
AAIC
983
DELISTED
Arlington Asset Investment Corp.
AAIC
$134K ﹤0.01%
35,523
+634
+2% +$1.98K
ACGN
984
DELISTED
Aceragen Inc
ACGN
$134K ﹤0.01%
2,148
-4,865
-69% -$279K
CSPR
985
DELISTED
Casper Sleep Inc.
CSPR
$129K ﹤0.01%
20,931
+4,957
+31% +$34K
RMNI icon
986
Rimini Street
RMNI
$457M
$128K ﹤0.01%
28,788
-23,028
-44% -$91K
RVSB icon
987
Riverview Bancorp
RVSB
$107M
$124K ﹤0.01%
23,619
CRVS icon
988
Corvus Pharmaceuticals
CRVS
$1.1B
$121K ﹤0.01%
33,968
-8,000
-19% -$32.2K
CTEV
989
Claritev Corp
CTEV
$399M
$119K ﹤0.01%
+374
New +$124K
MG icon
990
Mistras Group
MG
$477M
$115K ﹤0.01%
+14,785
New +$77.1K
III icon
991
Information Services Group
III
$204M
$106K ﹤0.01%
+32,225
New +$84.2K
NH
992
DELISTED
NantHealth, Inc
NH
$106K ﹤0.01%
2,178
-958
-31% -$36K
XXII
993
22nd Century Group
XXII
$1.28M
0
CHRA
994
DELISTED
Charah Solutions, Inc Common Stock
CHRA
$97K ﹤0.01%
+3,365
New +$98.5K
CRD.B icon
995
Crawford & Co Class B
CRD.B
$507M
$96K ﹤0.01%
13,330
DRRX
996
DELISTED
DURECT Corp
DRRX
$88K ﹤0.01%
4,267
+1,194
+39% +$22.7K
OVID icon
997
Ovid Therapeutics
OVID
$427M
$87K ﹤0.01%
37,843
-2,874
-7% -$13.4K
MNTX
998
DELISTED
Manitex International, Inc.
MNTX
$74K ﹤0.01%
14,300
ASUR icon
999
Asure Software
ASUR
$242M
$72K ﹤0.01%
+10,098
New +$77K
OPTN
1000
DELISTED
OptiNose
OPTN
$69K ﹤0.01%
+1,107
New +$67.8K

Similar funds

Jacobs Levy Equity Management's Q4 2020 Portfolio in Review

As of Q4 2020, Jacobs Levy Equity Management held 1,151 positions worth $11.4B, up 18% from $9.65B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Jacobs Levy Equity Management's Q4 2020 filing shows 138 new, 341 increased, 503 reduced and 146 closed positions. Its largest new stake was DexCom: 229,736 shares worth $21.2M. The largest sale was Optimum Communications Inc, an estimated $41M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Jacobs Levy Equity Management's largest Q4 2020 buy was DexCom: 229,736 shares worth $21.2M.
  • Jacobs Levy Equity Management added most to Amazon in Q4 2020, an estimated $32.1M increase.
  • Jacobs Levy Equity Management's biggest Q4 2020 reduction was Qualcomm, cutting an estimated $33.6M.
  • Jacobs Levy Equity Management fully exited Optimum Communications Inc in Q4 2020, selling an estimated $41M.
  • Jacobs Levy Equity Management's ten largest holdings make up 18% of its $11.4B portfolio in Q4 2020.
  • Jacobs Levy Equity Management opened 138 new positions and closed 146 in Q4 2020.
  • Jacobs Levy Equity Management's portfolio value rose 18% quarter-over-quarter to $11.4B.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.